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Abstract
Background
Despite vaccines and improved medical intensive care, clinicians must continue to be vigi-
lant of possible Meningococcal Disease in children. The objective was to establish if the pro-
calcitonin test was a cost-effective adjunct for prodromal Meningococcal Disease in
children presenting at emergency department with fever without source.
Methods and Findings
Data to evaluate procalcitonin, C-reactive protein and white cell count tests as indicators of
Meningococcal Disease were collected from six independent studies identified through a
systematic literature search, applying PRISMA guidelines. The data included 881 children
with fever without source in developed countries.The optimal cut-off value for the procalcito-
nin, C-reactive protein and white cell count tests, each as an indicator of Meningococcal
Disease, was determined. Summary Receiver Operator Curve analysis determined the
overall diagnostic performance of each test with 95% confidence intervals. A decision ana-
lytic model was designed to reflect realistic clinical pathways for a child presenting with
fever without source by comparing two diagnostic strategies: standard testing using com-
bined C-reactive protein and white cell count tests compared to standard testing plus procal-
citonin test. The costs of each of the four diagnosis groups (true positive, false negative,
true negative and false positive) were assessed from a National Health Service payer per-
spective. The procalcitonin test was more accurate (sensitivity=0.89, 95%CI=0.76-0.96;
specificity=0.74, 95%CI=0.4-0.92) for early Meningococcal Disease compared to standard
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testing alone (sensitivity=0.47, 95%CI=0.32-0.62; specificity=0.8, 95% CI=0.64-0.9). Deci-
sion analytic model outcomes indicated that the incremental cost effectiveness ratio for the
base case was £-8,137.25 (US $ -13,371.94) per correctly treated patient.
Conclusions
Procalcitonin plus standard recommended tests, improved the discriminatory ability for fatal
Meningococcal Disease and was more cost-effective; it was also a superior biomarker in in-
fants. Further research is recommended for point-of-care procalcitonin testing and Markov
modelling to incorporate cost per QALY with a life-time model.
Introduction
Diagnostic tests rarely give a definitive dichotomous result (a diagnosis of disease or no disease)
but more often offer results on a continuous likelihood or probability scale. Thus a test thresh-
old is required to indicate the likelihood of disease. With imperfect tests such thresholds are
difficult to determine. Avoiding underdiagnoses and ensuring diagnosis of each life threatening
case is more important than the costs and consequences attendant upon a falsely positive diag-
nosis in a healthy person [1].
Meningococcal Disease (MD) is an example of a potentially fatal illness if diagnosis is
missed or delayed. The meningococcus invades the thin membrane covering the brain and spi-
nal cord (meningococcal meningitis) or blood (meningococcal sepsis), and often both [2]. MD
mostly affects children less than five and young people of 17 to 19 years of age. Vaccines are
available to protect against different strains of the microorganisms. The rates of MD have de-
clined. However, serogroup B meningococcal (MenB) disease is the most common cause of
MD in older children, young adults in the United States (US)[3] and, recently, across age
groups in the UK accounting for 85–90% of cases [4]. In 2009–10 there were around 1000 labo-
ratory-confirmed MD cases in the UK and Ireland [5]. The perception of prognosis for MD
now is that few cases result in death probably because of improved intensive care provision.
The perceived lower case fatality may paradoxically delay the uptake of vaccines, which must
undergo stringent national regulatory authorisation [6]. The Men B vaccine is not approved in
the US but it has been used to help control specific outbreaks in the US. The licensed vaccine is
not routinely recommended for use in Europe, Canada, and Australia. In March 2014, The
Joint Committee on Vaccinations and Immunisation (JCVI) reviewed their decision of insuffi-
cient evidence to support routine MenB vaccination for using Bexsero (Novartis Vaccines and
Diagnostics S.r.l.) in the UK to recommend a carefully planned vaccination programme for
MenB initially in infants [7]. Meanwhile, clinicians must continue to be vigilant regarding pos-
sible MD in children and young people of all ages, as, even with constantly improving paediat-
ric intensive care services, more children will survive invasive MD with disability [8,9].
Most paediatric patients with MDmake a full recovery but some are left with critical compli-
cations [2, 8–11]. NICE has estimated that of the survivors 3% have amputations, 3% have other
orthopaedic complications for example damage to growth plates and 13% have skin complica-
tions that require reconstructive surgery [12]. A recent UK case-control study into the outcomes
of invasive MD (strain MenB) in survivors reported: around 10% of children suffered major dis-
abling deficits (seizures, hearing loss, amputations, visual loss and loss of speech or ability to un-
derstand speech) and more than a third had minor deficits (other physical, cognitive, and
psychological abnormalities) [9]. These problems severely affect the quality of life experienced by
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survivors and their families [2]. Adverse outcomes in each survivor of severe MD are estimated
to accumulate life-long costs totalling £1.3 million [13]. Early detection and prompt treatment of
early stage MD (prodromal stage) can halt disease progression and reduce the severity of the clin-
ical outcome. Prodromal stage MD is extremely difficult to clinically distinguish from less serious
illnesses. If not detected early, someMD cases rapidly escalate to a fulminant illness. Results
from traditional laboratory blood tests for MD detection are usually not available early enough
to influence treatment. It has been estimated that 50% of children presenting to General Practi-
tioners (GPs) in the UK with prodromal MD are misdiagnosed with other conditions and sent
home [14]. Conversely, it is well recognised that misdiagnosis of MD also occurs leading to
many children needlessly being admitted to hospital and treated with intravenous antibiotics.
Levels of procalcitonin (PCT) in the blood, a naturally occurring hormone, rise within two
hours of the onset of an invasive infection, peak at six hours and remain elevated for a further
24 hours. PCT can be detected rapidly and accurately using a near-patient test (B-R-A-H-M-S
PCT, ThermoScientific). PCT is not routinely measured in Emergency Departments (EDs) de-
spite its potential usefulness as an early indicator of infection [15–19]. While never completely
ruling out MD when combined with a careful clinical assessment, a PCT test could be useful in
the assessment of a child with nonspecific fever.
Existing NICE clinical guidelines (CG102) on the management of bacterial meningitis and
meningococcal septicaemia in children and young people in the UK do not recommend the
use of serum PCT levels for prediction of disease [12]. C-reactive protein (CRP) and white cell
count (WCC) measurement is recommended as a potential indicator of bacterial meningitis in
febrile children with a rash although these are non-specific indicators of severe infection. Scot-
tish Intercollegiate Guidelines Network (SIGN) acknowledge that serum PCT levels could help
distinguish patients with a fever without source (FWS) who have serious bacterial infection
(SBI) from those who do not [20]. High PCT levels at the time of hospital admission in chil-
dren with MD have been associated with the severity of outcome, sepsis and death [21–23].
Thus, based on current evidence, the SIGN guidelines state that clinicians should be aware that
a high PCT level (>150ng/l) is associated with high mortality.
PCT is a good indicator of early SBI [24–28]. In this review we wish to establish if the PCT
test’s diagnostic performance is better than that of CRP and WCC for the detection of the pro-
dromal stage MD in children presenting at ED with a FWS. However, test performance alone is
of little relevance detached from clinical decision-making. To determine the value of using a
PCT test as a prompt indicator of prodromal MD in febrile children, we evaluated the test ac-
curacy and cost-effectiveness in plausible clinical scenarios using data from independent stud-
ies carried out in developed countries. In addition, an analysis of unpublished results was
included from a previous study carried out in Belfast.
Methods
Selection Criteria
1. Children aged 1 month to 16 years (as a subgroup) with suspected MD were eligible for in-
clusion if: they had FWS, were admitted to the ED or initial admissions unit of a hospital in
a middle-high income country, had serum PCT tested within 4 hours of arrival and had no
previously known bacterial or viral infection. FWS was defined as a temperature greater
than 38 degrees Celsius with no apparent source after clinical history and examination.
2. The PCT test employed was a luminescence immunoassay (Brahms Diagnostica GmbH, D-
12099 Berlin, Germany) or very similar technology. Studies may or may not have measured
CRP andWCC. It was assumed that CRP and WCC analyses were performed in quality
Procalcitonin Test for Meningococcal Disease in Children
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assured hospital laboratories. For comparison reasons the blood samples for each test (PCT,
CRP andWCC) had to be taken at the same time during initial clinical presentation.
3. MD caused byNeisseria meningitidiswas confirmed using one of the following ‘gold standard’
tests: conventional culture or polymerase chain reaction (PCR). The blood or cerebrospinal
fluid (CSF) used for these tests was taken at the same time as sampling for PCT testing:
Data Source
To identify all prospective and retrospective studies and Randomised Controlled Trials (RCTs)
a literature search, using search terms relating to children, FWS, Meningococcal, bacterial
meningitis and PCT was carried out in August 2011 (Table A in S1 File). Ovid MEDLINE(R)
and MEDLINE(R) In-Process & Other Non-Indexed Citations, Embase, HMIC Health
Management Information Consortium, Web of Knowledge Web of Science, BIOSIS Citation
Index, BIOSIS Previews, EBSCO CINAHL Plus and The Cochrane Library inclusive of
Cochrane Controlled Trials Register were searched. Additional searches involved ZETOC
(general and conference), Index to Thesis of Great Britain and Ireland, Pro-Quest Education
Journals, Turning Research into Practice (TRIP), National Library for Health (NLH), e-Guide-
lines, NICE guidelines, SIGN guidelines and Clinical Trials.gov. Hand-searching of reference
lists in relevant articles was carried out.
Abstracts were reviewed and full-text articles were obtained for those studies that met the el-
igibility criteria. The correspondence authors of relevant studies were contacted to request raw
data for PCT and, if available, CRP and WCC to enable calculation of true positives (TP), false
positives (FP), false negatives (FN), and true negatives (TN) with MD confirmation by culture
or PCR microbiological testing. Each individual study was assessed for quality by using the re-
vised tool for the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) (S1
PRISMA Checklist)
Statistical analysis
PCT, CRP and WCC levels for cases of microbiologically confirmed MD or not MD seen in
ED or on admission were analysed per study and within a combined studies pooled data set.
Receiver operator curve (ROC) analysis of pooled study data was used to compare diagnostic
performance of each test from the areas under the curve (AUC) with 95% confidence levels
(CIs). Optimal diagnostic test cut-off levels were found using the Youden Index. For each test,
2 x 2 tables were constructed using optimal diagnostic test cut-off levels.
Meta-analyses, employing the random-effects and Hierarchical Summary ROC models
(HSROC), were carried out to demonstrate relative risk (RR) for the studies using the optimal
diagnostic test thresholds for early MD. The summary threshold for each test was identified on
the HSROC curve for each test. Subgroup meta-analysis of test performance was undertaken
for different age-groups. Statistical analysis was undertaken using Stata/IC software version 11
(StataCorp, College Station, Texas).
Assessment of heterogeneity. To quantify the extent of between study variations (hetero-
geneity), the I2 Statistic was calculated prior to meta-analysis. Publication bias was explored
using Egger’s test and funnel plots.
Cost-effectiveness analysis
A decision analytic model was constructed to establish the cost-effectiveness of PCT, CRP and
WCC tests compared with CRP and WCC tests (standard care) in the diagnosis of MD in
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children presenting at ED with a FWS. Fig 1 presents a simplified illustration of the decision
tree. The model makes a clear link between the diagnostic accuracy of a given test, the impact
on treatment decisions and the ultimate effect on correct treatment and costs [29]. The cost-ef-
fectiveness analysis was conducted from the perspective of the National Health Service (NHS)
and only included hospital costs associated with the diagnosis and follow-up. Clinical pathways
were detailed for four diagnostic groups (i.e. those with true positive results, false negative re-
sults, true negative results and false positive results) with a further pathway to represent the
level of illness (severe, moderate or mild). The probability distributions relating to the four di-
agnostic groups were derived from the meta-analysis; while the distributions for the severity of
illness were based on data from a single source [30]. Costs and outcomes of each of the groups
were assessed. Multiple clinical pathways were based on an outcomes study among children
with suspected MD assessed at the RBHSC [30] and costed in UK Sterling (£) using unit costs
from the National Schedule of Reference Costs 2010–2011 of NHS Trusts and Primary Care
Trusts combined [31] (Tables D and E in S1 File). The unit costs for hospital spells do not in-
clude costs associated with paediatric critical care (PICU). These costs were therefore added
separately. The tests were assumed to be carried out on the same blood sample collected from
the ill child on presentation to the ED. No discounting of costs and health outcomes were ap-
plied as the time horizon was less than 1 year. The cost-effectiveness was expressed in terms of
the incremental cost-effectiveness ratio (cost per correctly treated patient). A correct diagnosis
was defined as either a true positive or a true negative result.
Sensitivity analysis. One-way sensitivity analysis was used to explore the impact of alterna-
tive assumptions and to assess the effect of uncertainty. The analysis was performed by altering
Fig 1. Decision tree for clinical pathway for children with fever without source.
doi:10.1371/journal.pone.0128993.g001
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the diagnostic thresholds for each test option (derived from the summary HSROC statistics)
with the effects of these changes on the incremental cost-effectiveness ratios subsequently
derived.
Results
Study identification
Of the 790 studies identified and screened 46 citations were selected for full text review. While
20 studies were deemed relevant for inclusion only six authors [19,21,32–35] provided suffi-
cient raw data on PCT and/or CRP andWCC levels with corresponding microbiological results
confirming MD and non-MD cases to conduct a pooled individual patient level analysis of in-
dependent studies (Fig 2 and Table B in S1 File). These six studies [19, 21, 32–35] reported on
881 children with FWS and provided the following data: 672 results for PCT, 518 for CRP and
592 for WCC (517 matched CRP and WCC results). Unpublished data from a Doctoral thesis
[19], approved by the local Research Ethics Committee and supported by a research grant from
The Royal Belfast Hospital for Sick Children (RBHSC), was relevant and was included in this
selection.
Quality of included studies
In general, the quality of included studies was high (Fig 3). The data from the six studies in-
volved children with FWS, provided adequate descriptions of the diagnostic tests and reported
microbiological blood/CSF culture and/or PCR for reference test confirmation of MD. Two of
six studies were focussed on SBIs in ED [33,34] and three [19, 21,35] focused on the MD care
pathway within paediatric EDs. Sources of heterogeneity included the study sample size and
the prevalence of MD (S1 Fig). In two of the six studies higher MD prevalence was related to
the operation of a specific care pathway in the paediatric ED for patients with suspected MD
[19, 21] and a local outbreak of MD in the community [35]. Table 1 summarises the character-
istics of chosen studies.
Optimal diagnostic threshold
The test thresholds applied in the selected studies were not always for MD detection but to in-
dicate the presence of SBI. The optimal diagnostic test thresholds for early MD detection were
determined as 193ng/ml for PCT, 28 mg/l for CRP and 16 x 109 /l for WCC. The Area Under
Curve (AUC) for ROC plots for individual tests at these thresholds demonstrated that the PCT
test with AUC = 0.95 (95% CI; 0.93 to 0.97) out-performed both CRP, AUC = 0.83 (95% CI;
0.79 to 0.87), and WCC, AUC = 0.67 (95% CI; 0.61 to 0.72) (S2 Fig)
Meta-analysis
Values for sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio
(NLR) and odd ratio (OR) of the summary point from HRSOC plots for each test (Fig 4) are
presented in Table 2. These show PCT as the most accurate test (sensitivity 89%, 95%CI 76–
96%; specificity 74%, 95%CI 40–92%) for early MD compared to CRP and WCC. PCT has the
best PLR (3.4, 95%CI 1.2–9.3) and most likely to suspect MD (RR of MD 4.71 95% CI 1.9–
11.9) in a child with FWS compared to the CRP test (RR = 1.7, 95% CI 1.0–2.9) and WCC
(RR = 1.4, 95% CI 0.9–2.3) (S3 Fig). In clinical practice, the existing tests CRP and WCC are
normally used together as indicators for MD. Raised values of both (CRP+WCC+) with non-
specific symptoms would be viewed as a standard approach in distinguishing possible MD [12]
when awaiting confirmatory microbiological results. To reflect this pragmatic use of both tests
Procalcitonin Test for Meningococcal Disease in Children
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Fig 2. Selection of studies included in meta-analysis.
doi:10.1371/journal.pone.0128993.g002
Procalcitonin Test for Meningococcal Disease in Children
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the combined performance of CRP andWCC, at optimal cut-offs levels was evaluated
(Table 2). The CRP and WCC combined test had a sensitivity of 47% (95%CI 32–62) and spec-
ificity 80% (95%CI 64–90).
Sub-group analysis. The effect of the age (of febrile children) on the test performance was
explored at optimal cut-offs. The overall estimated relative risk (RR) of PCT indicating MD
(RR 13.2; 95% CI 4.3–40.5) was greater than that of CRP (RR 3.0; 95% CI 0.8–11.1) and WCC
(RR 1.6; 95% CI 1.2–2.1). Heterogeneity across age groups was not significant for WCC (I2 =
0%) and moderate for PCT (I2 = 52.5%) tests but was significant (I2 = 89.6%) for the CRP test.
The PCT test for distinguishing prodromal MD appeared more accurate in very young (1–12
months of age) febrile children (sensitivity 95%, specificity 91%, positive likelihood ratio (PLR)
Fig 3. QUADAS-2 results.
doi:10.1371/journal.pone.0128993.g003
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10) (S4 Fig, Table C in S1 File). Combined CRP and WCC had a greater PLR in children aged
5–9 years (sensitivity 58%, specificity 76%, PLR 3.8).
Cost-effectiveness analysis
Base case. The decision analytic model was populated with the sensitivity and specificity
data derived from the HSROC analysis summary point estimates, applying optimal cut-offs for
each test (Table 2). In keeping with the findings of better diagnostic accuracy for PCT, the cor-
responding ICER for the base case was -£8,137.25 (US-$13,371.94) per correctly treated patient
(Table 3). The negative value is a result of PCT + standard care being more effective and cost-
ing less than standard care i.e. it is the dominant strategy. Thus, introducing the PCT test and
correctly treating more patients, despite an additional outlay of £11 (US $18.08) per test, would
result in cost savings (from the payer perspective). These savings were largely attributable to
improvements in the diagnostic test’s sensitivity and specificity compared to the combined
CRP and WCC tests, resulting in fewer patients being incorrectly treated (due to false positive
Table 1. Summary of the characteristics of chosen studies and MD events published.
Study
Ref.
Setting Presentation Age Exclusion Prevalenceb PCT assaya PCT cut-
off (ng/
ml)
Sensb Specb
%
(95%
CI)
Study Outcome
32 Hospital Admission to
hospital
suspected
meningitis
1 mnth
to 14
yrs
n/a 022(009–
043)
PCT-LIA 0.5 83
(60–
99)
57
(34–
77)
Elevated PCT levels
in children with
suspected meningitis
suggests SBI
21 Paediatric
Hospital
fever, rash,
illness
1
mnth-
16yrs
n/a 064(055–
072)
PCT-LIA 2 94
(85–
98)
93
(80–
98)
PCT is a more
sensitive predictor for
MD than CRP and
WCC
33 Paediatric
ED
Fever <12hr 1
mnth-
12yrs
n/a 046(031–
062)
PCT-LIA 2 75
(72–
99)
63
(41–
82)
Distinguishing SBI
from viral & localized,
PCT was more
sensitive than CRP
for indication of SBI
19 Paediatric
ED
Fever, rash,
signs of
meningitis,
suspected
meningitis
<15
yrs
n/a 037(023–
052)
PCT-Q 1.01 83
(58–
96)
74
(56–
87)
PCT as predictor of
early MD was better
than CRP and WCC
35 Paediatric
ED
Non-speciﬁc
fever
<14
yrs
and
14–40
yrs
UTI 068(059–
076);<14 yrs•)
0029(001–
003);adults
PCT-Q-LUMI 2;for
children,
0•5;for
adults
94
(75–
99)
84
(83–
87)
PCT as a diagnostic
indicator for MD in
children with non-
speciﬁc fever
34 Paediatric
ED
No identiﬁed
source of fever
after history
taking and
physical
examination
1–36
mnths
UTI as a
sub-group
0003(00001–
0022)
PCT-Kryptor 0.2 100
(5–
100)
68
(63–
74)
CRP, PCT and WBC
had similar
diagnostic properties
and superior to
clinical evaluation in
predicting SBI in
children of 1–36
months•
Abrev. ED Emergency Department
aAssays made by BRAHMS GmbH (Hennigsdorf, Germany)
bBased on individual study diagnostic cut-off as publishedx
doi:10.1371/journal.pone.0128993.t001
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CRP/WCC diagnoses) or treatment delays among those with false negative CRP/WCC results
(Tables D and Ein S1 File).
Sensitivity analysis. The one-way threshold sensitivity analyses explored uncertainty in
the thresholds used for the base case analysis. The results of the sensitivity analyses showed lit-
tle variation across the ranges tested for the sensitivity and specificity parameters for the PCT,
CRP and WCC tests (Table F in S1 File). The incremental cost-effectiveness ratios remained
Fig 4. HSROC plots for selected studies for PCT, CRP andWCC individual tests and CRPwith WCC.
doi:10.1371/journal.pone.0128993.g004
Procalcitonin Test for Meningococcal Disease in Children
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<-£2,000 per correctly treated patient with the exception of when the threshold PCT ap-
proached 0.2ng/ml. Thus, the sensitivity analyses indicate an improvement in diagnostic per-
formance that is translated into cost savings. One-way sensitivity analyses were also conducted
using the HSROC statistics derived following the exclusion of the study outlier. Results were es-
sentially unchanged because the ICER indicated that PCT testing was the dominant
diagnostic strategy.
Discussion
The NICE clinical guidelines (CG102) for the management of bacterial meningitis and menin-
gococcal septicaemia in children and young people recommend non-specific laboratory tests
including CRP andWCC as being useful investigations for those presenting with FWS [12].
However, there were no recommendations concerning PCT testing. This led us to re-examine
the research on the performance of PCT as a marker for early MD. We used decision modelling
to compare short-term costs and benefits of using a PCT test with the recommended CRP and
WCC for children with FWS presenting at ED.
In the case of early MD detection, it is desirable for a test to have high test sensitivity to re-
duce the chance of a missed diagnosis of potentially fatal MD. Many have demonstrated the
PCT test to be more accurate for predicting invasive bacterial infections [36–45] sepsis [46, 47]
and so ruling-out serious bacterial infection [28,48–50]. Within these past studies, a range of
diagnostic thresholds has been used for the PCT test. After applying a diagnostic test threshold
of 2 ng/ml as an indicator of possible MD previous authors found the sensitivity of the PCT
test to range from 94 to 100% and specificity 84 to 100% [33, 35]. A limitation of the PCT test
is that it will not distinguish between SBIs but a child presenting with FWS and an elevated
PCT level is more likely to have a SBI with more severe outcomes. It is important to emphasise
that alongside the clinician’s judgement, the PCT test is a useful indicator of MD when com-
bined with standard laboratory tests and clinical symptoms. The rapid rise of PCT levels in re-
sponse to a fulminant SBI such as MDmake it a more valuable test in an ED setting.
Careful consideration is required in regard to the threshold level used to indicate different
serious infections as it is a source of heterogeneity in test accuracy studies [51]. We were able to
Table 2. Meta analysis of studies; summary point statistics of HSROC analysis for PCT, CRP andWCC diagnostic testsa.
Diagnostic Test Sensitivity Speciﬁcity PLRa NLRb ORc Prevalence
% 95% CI % 95% CI 95% CI 95% CI 95% CI
PCT 89 76–95 74 40–92 3.4 1.2–9.3 0.2 0.07–0.3 22.5 5.7–87.8 0.3
CRP 74 52–88 54 31–75 1.6 1.1–2.4 0.5 0.3–0.9 3.2 1.4–7.5 0.2
WCC 50 40–61 68 54–79 1.6 1.0–2.4 0.7 0.6–0.9 2.2 1.1–4.2 0.2
Combined CRP & WCC 47 32–62 80 64–90 2.3 1.2–4.6 0.7 0.5–0.9 3.5 0.4–8.9 0.2
ausing optimal diagnostic cut-offs
b conventional positive likelihood ratio (PLR)
c conventional negative likelihood ratio (NLR) d diagnostic odds ratio (OR)
doi:10.1371/journal.pone.0128993.t002
Table 3. Results of base case cost-effectiveness analysis of test strategies for diagnosis of MD.
Test Cost (C) Incremental Cost Effectiveness (E) Incremental Effectiveness C/E ICER
Standard care £3476.88 0.734 £4736.89
PCT + standard care £3061.88 -£415.00 0.785 0.051 £3900.48 -£8137.25
doi:10.1371/journal.pone.0128993.t003
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determine optimal cut-off levels for MD of each test, among children who presented at ED
with FWS, by pooling the provided raw data. These diagnostic thresholds were compared to
available literature and discussed with clinicians to ensure they were plausible and appropriate
thresholds for meaningful decision analysis. When different thresholds have been employed,
pooling data from a number of studies [52] will clearly affect the estimated sensitivity and spec-
ificity (known as the threshold effect). HSROC analysis was thus employed as the most appro-
priate method to determine the overall accuracy of a diagnostic test from data spanning 6
studies, using the optimal thresholds for each test. Although we selected similar studies, for ex-
ample, for suspected disease, when and what PCT assay was used for suspected MD, substantial
heterogeneity was apparent in our meta-analysis. Unrecorded and demographic differences
may account for this in addition to variation in disease prevalence [53]. The 14 studies exclud-
ed due to no availability of raw data were similar to those 6 studies included in that they also
took place in middle to high income countries (Europe n = 11, US n = 1, New Zealand n = 1
and Saudi Arabia n = 1), investigated patients with fever and a temperature38°C, had blood
tests and MD reference test taken on admission to paediatric emergency department (n = 9),
hospital ward (n = 4) or ICU (n = 1), included children of varied age, with eight studies includ-
ing infants only ( 3 years of age) and six studies including those up to 16 years of age, and fi-
nally all studies described the PCT test, MD reference test and other blood tests taken (CRP or
WCC). The median incidence of the confirmed MD (n = 8), for these 14 studies that could not
be included in the meta-analysis, was 5.2% (range 0.3–13%). A strength of this review was that
all studies recorded appropriate robust reference tests for confirmation of MD. Although diag-
nostic accuracy may have been compromised by some study bias or demographic variation, the
PCT test had greater sensitivity for suspected MD. At the same time, its higher specificity also
implies fewer false positive results.
The better sensitivity of the PCT test also provided the basis for a more cost-effective test
than the currently recommended CRP and WCC tests for the detection of early stage MD in
children with FWS. A recent FEVER study found that for 3,893 febrile children, many present-
ing at hospital EDs, the total WCC failed to detect the most common SBI across a range of ages
with a sensitivity, specificity and ROC AUC of 47%, 76% and 0.68 respectively [54], very simi-
lar to that found here. For the current review, overall test accuracy was superior for PCT when
compared either with combined use of CRP andWCC or as individual tests. However, specific-
ity for the PCT test and for combined CRP andWCC were similar. From the meta-analysis of
pooled data across age groups the PCT test was a good biomarker in infants (1 month to 1 year
of age): this is clinically very important as MD is more common in very young children and
more difficult to diagnose in the prodromal stages. Recent interest has been in those under the
age of three. A study of 226 febrile children 36 months old or younger who presented to four
EDs with suspected SBI found PCT to be a more accurate biomarker than traditional screening
tests for identifying young febrile infants and children with serious SBIs [55]. In this case the
area under ROC curve for PCT as a test for SBIs was higher in comparison at 0.80 (95% CI 0.71
to 0.89).
Despite its superior performance it is reasonable to ask if the PCT test alone would offer a
cheaper point of care option delivering quicker results. Our decision analytic model provided a
clear indication of the cost-effectiveness of adding the PCT test to standard care. However, we
should exercise some caution before concluding that these findings support the introduction of
PCT testing into routine clinical practice. Firstly, we only considered the immediate impact of
each diagnostic strategy, with the associated short-term costs and benefits. Secondly, the cost-
effectiveness for each diagnostic strategy was defined as the cost per correctly treated patient.
Further research is recommended to extend the analysis with a Markov model that could incor-
porate the impact on longer term quality-adjusted life years to calculate cost per QALY, in line
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with current guidance [56]. Nevertheless, our analysis suggests that the PCT test would offer
savings and benefits by expediting the correct treatment for more patients and therefore reduc-
ing risks of further complications in the long term.
The difficulty in diagnosing MD in the early stages in young children is widely acknowl-
edged. Its distinction from viral infection and other presentations is crucial for appropriate and
prompt management. The consequence of not diagnosing MD early is a significant increase in
morbidity and mortality. Conversely, if a diagnosis of MD is made incorrectly, some children
may be unnecessarily treated with intravenous antibiotics leading to potential side-effects such
as anaphylaxis or increasing antibiotic resistance.
Conclusion
In summary, an optimal PCT level of>1.93 ng/ml could indicate early stage MD in paediatric
patients presenting with FWS more quickly (in less than 1 hour) than currently recommended
tests. Even when used with conventional tests it has the potential to be more cost-effective and
can contribute to better antibiotic stewardship [57, 58].
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